Abiraterone
- OralAbirateroneZytiga
Mechanism of Action
- Inhibits 17-α hydroxylase / C17,20-lyase (CYP17) which is expressed in prostatic tumour tissue and is required for androgen synthesis.
Clinical Use
Indications
- Metastatic prostate cancer.
- Adverse Effects
- Fatigue
- Hot flushes
- Hypokalaemia
- Hypertension
- Peripheral oedema
- LFT derangement
- Diarrhoea
- Anaemia